Amarin Corp Plc (AMRN)

[JBWIN]

Click on Learn More button to get guidelines by medical society...

https://www.vascepahcp.com/guidelines/#:~:text=American%20Diabetes%20Association%20(ADA)%20Standards,%2D499%20mg%2FdL).

American Heart Association (AHA) Science Advisory:

Released an advisory statement identifying icosapent ethyl as the first non–LDL-focused lipid therapy to demonstrate CV benefit. IPE was further recommended to be considered first-line therapy for patients with T2DM and CAD whose triglycerides remain elevated (>135 mg/dL) despite maximally tolerated statin and lifestyle changes.1

Learn more
American Diabetes Association (ADA) Standards of Medical Care in Diabetes for 2019:

ADA gives icosapent ethyl level “A” recommendation for patients with diabetes and ASCVD or other CV risk factors on a statin with controlled LDL-C and elevated TG (135-499 mg/dL).2

"It should be noted that data are lacking with other omega-3 fatty acids and results of the REDUCE-IT® trial should not be extrapolated to other products"
Combination therapy (statin/fibrate) has not been shown to improve atherosclerotic cardiovascular disease outcomes and is generally not recommended
Learn more
American Association of Clinical Endocrinologists (AACE) Consensus Statement:

Recommends to add icosapent ethyl 4 g/day if high ASCVD risk on maximally tolerated statins and TG 135-499 mg/dL.3

Learn more
National Lipid Association (NLA) Scientific Statement:

Class I, Level B-R (STRONG) recommendation for the CV risk-lowering effects of icosapent ethyl for high-risk and very-high-risk patients with TG 135-499 mg/dL on statin therapy.4

Learn more
European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines:

Recommend that icosapent ethyl, 2g twice a day, should be considered for patients with CV disease who have TG levels 135 mg/dL to 499 mg/dL despite statin treatment, which places them at high risk of CV events, such as heart attack, stroke, or death.5

Learn more
Leading medical societies emphasize that clinical results with IPE should not be generalized
to any other product